[1].NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. Version 1.2025 审批编号:CN-146864有效期至:2025-01-06 本材料由阿斯利康提供,仅供医疗卫生专业人士参考 更多医疗资讯,...
[5]Hallek M, Cheson BD, Catovsky D,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348. [6]Wierda WG, Raws...
参考文献: [1]NCCN CLL/SLL Guidelines 2024 V1. [2]CSCO淋巴瘤指南2023. [3]Jeff P. Sharman, et al. 2023 ASH. Abstract 636. [4]Kohrt H E, et al. Blood, 2014, 123(12): 1957. [5]Golay J, et al. Haematol...
Investigators assessed disease response at least every 6 months, using modified iWCLL guidelines [CLL: Hallek et al. 2008; SLL: Cheson et al. 2014]; a response category of " no evidence of progressive disease " was also available. Results: In total, 170 patients with CLL/SLL were treated...
For relapse of disease that occurs more than 3 y later, re-treat with first-line therapy; if relapse occurs after less than 2 y, see the NCCN guidelines for second-line therapies based on age and comorbidities [12] Locoregional radiation therapy is appropriate for patients with Ann Arbor ...
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 21, 2024. To view the most recent ...
Accessed March 14, 2024. https://www.cancer.gov/publications/dictionaries/cancer-terms 6. IMBRUVICA® (ibrutinib) Prescribing Information. 7. Vernooij RWM, Willson M, Gagliardi AR. Characterizing patient-oriented tools that could be packaged with guidelines to promote self-management and guideline ...
At month 15, the rate of complete response—in accordance with the International Workshop on CLL Guidelines—was 31.05% in the chemoimmunotherapy group (n = 71), 49.4% in the venetoclax/rituximab group (n = 117), 56.8% in the venetoclax/obinutuzumab group (n =...
Guidelines for Mesothelioma Now Offer More Treatment Options Immunotherapy Advances in Small Cell Lung Cancer Treatment Ide-cel in Multiple Myeloma Post-Transplant: Insights From Garfall NIH Funding Fuels Advances in Cancer Treatment and Therapies ...
Essentially, the guidelines say that if someone has a high TLS risk, then they should be admitted into the hospital for the initial venetoclax escalation to make sure that if TLS occurs, it can be managed.If they have low TLS, that can be done as an outpatient. What we found in our ...